Glibenclamide - Biogen

Drug Profile

Glibenclamide - Biogen

Alternative Names: BIIB 093; CIRARA; Diabeta; Glybenclamide; Glyburide for injection; RP-1127

Latest Information Update: 04 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Remedy Pharmaceuticals
  • Developer Biogen; Ohio State University; Remedy Pharmaceuticals
  • Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas
  • Mechanism of Action ABCC8 protein antagonists; TRPM4-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries; Stroke
  • New Molecular Entity No

Highest Development Phases

  • Phase III Stroke
  • Phase II Brain injuries; Spinal cord injuries

Most Recent Events

  • 04 Oct 2018 Phase II for Spinal cord injuries is still ongoing in USA (NCT02524379)
  • 04 Sep 2018 US FDA grants Special Protocol Assessment (SPA) to the phase III CHARM study in Stroke
  • 14 Aug 2018 Phase-III clinical trials in Stroke (In adults, In the elderly) in Hungary (IV) (EudraCT2017-004854-41)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top